NHS Approves First Drug That Delays Type 1 Diabetes

For the first time, the NHS in England will offer a drug that does not treat type 1 diabetes but delays it.

The National Institute for Health and Care Excellence has recommended teplizumab, sold as Tzield and made by Sanofi, for people aged eight and over who are in the earliest stage of the condition: after the immune system has begun attacking the pancreas, but before any symptoms appear. In trials it delayed the onset of symptomatic, insulin-dependent diabetes by an average of nearly three years.

That window matters more than it sounds. Type 1 diabetes is a lifelong condition in which the immune system destroys the insulin-producing beta cells in the pancreas, and about 400,000 people in the UK live with it. Teplizumab is given as a single course and works upstream of insulin, training the immune system to ease its assault on those cells rather than replacing the hormone they make.

NICE estimates around 1,100 people could be eligible in the first year, falling to roughly 820 a year later. The modest figure points straight to the catch: to benefit, you have to be found in time.

"This is a genuinely exciting recommendation. For the first time, we have a treatment that can give people diagnosed at an early stage of type 1 diabetes precious extra time before they need to manage the full demands of the condition."

Helen Knight, director of medicines evaluation, NICE

Diabetes UK called it the start of a new era. "For the first time in 100 years, we are moving beyond insulin, with a medicine that targets the root cause of the condition," said Dr Elizabeth Robertson, the charity's director of research, who pressed for "fair and equitable access for everyone who is eligible."

The screening gap

Here is the problem the approval exposes. Teplizumab only helps people identified at stage 2, and that stage is silent, caught only by a blood test for the autoantibodies that signal the immune attack. The UK has no national screening programme, so most people still learn they have type 1 the hard way, in a hospital, already needing insulin. Two research studies are probing how to change that: the Diabetes UK-backed ELSA study, screening children aged two to 17, and T1DRA, screening adults from 18 to 70.

For the families already inside that window, the value is plain. Elena Boichak, from Newbury, found out her son Dima had stage 2 type 1 after enrolling him in the ELSA study at nine.

"As a mother, the most valuable thing teplizumab has given us is time. Every month and every year that Dima can continue being a child without insulin injections, carb counting and the daily burden of type 1 diabetes is incredibly precious."

Elena Boichak, parent

A drug that can buy a child three more years of an ordinary childhood is a genuine advance. Whether it reaches more than a sliver of the people it could help now turns on a less glamorous question than the science: whether the country decides to go looking for those who do not yet know they are ill.